Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/05/24
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdatePRNewsWire • 08/05/24
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024PRNewsWire • 07/22/24
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should KnowZacks Investment Research • 06/21/24
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdatePRNewsWire • 05/13/24
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024PRNewsWire • 04/29/24
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?Zacks Investment Research • 04/15/24
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024PRNewsWire • 04/10/24
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/26/24
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatePRNewsWire • 02/26/24
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024PRNewsWire • 02/14/24
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a TurnaroundZacks Investment Research • 01/12/24
Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goalMarket Watch • 01/05/24
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)PRNewsWire • 01/05/24